GLP-1/Weight Loss

Walgreens steps into a new healthcare role, guiding millions of Medicare patients to affordable GLP-1s. Is this the future of the American pharmacy?

Professor Jason Chin’s Heinrich Wieland Prize signals a new era. His work in synthetic biology is enabling Constructive Bio to forge a new class of drugs.

A new CMS program offers seniors blockbuster obesity drugs for $50. But this temporary fix raises profound questions about cost, access, and our healthcare future.

A new RNA therapy for obesity is advancing in trials. It promises to reduce harmful visceral fat, preserve muscle, and may only require a twice-yearly dose.

Telehealth platforms like TWL promise easier access to weight-loss drugs, but a closer look reveals a complex world of insurance battles and risky compounds.

Telehealth firms now offer needle-free weight-loss pills. As companies like FitRx expand access, they enter a regulatory minefield of unapproved drugs.

New telehealth platforms promise to unlock Zepbound by navigating insurance mazes. But are they building a safe superhighway or a risky digital backroad?

Telehealth firm Zealthy touts easy access to Zepbound, but a major federal lawsuit alleges a pattern of fraud, dangerous prescribing, and consumer deceit.

Eli Lilly's partnership with ŌURA isn't just a perk. It's a strategic move to solve the GLP-1 adherence problem and build a data-driven moat in a $100B market.

A top Trustpilot rating isn't just a marketing win. It's a signal of a quiet revolt in women's healthcare, where integrated models are challenging the status quo.

Rexall's new at-home weight management program signals a major shift, blending virtual doctor visits, GLP-1s, and pharmacist support. What does this mean for patients and the future of Canadian healthcare?

With no approved drugs for the Bundibugyo Ebola outbreak, 101 Therapeutics releases un-reviewed data, forcing a global health showdown between speed and safety.

Silo Pharma has navigated a critical headwind, regaining Nasdaq compliance. This move provides vital stability, allowing the firm to focus on its true test.

A new drug from Cambrian Bio shows promise in activating a key metabolic switch. This could lead to treatments that burn fat while preserving muscle mass.

A 'dream team' of pharma veterans has raised $180M to advance a next-gen oral drug, promising to transform the multi-billion dollar IBD market.

At BIO 2026, Transpire Bio isn't just presenting; it's pitching a new paradigm for medicine, using inhalation to tackle everything from diabetes to cancer.

Delisted and facing market headwinds, Allurion is executing a reverse stock split. Can this financial maneuver revive its stock and fund its U.S. expansion?

Laprophan's acquisition of Rivopharm is more than a deal; it's a strategic blueprint for emerging market players aiming for the global pharmaceutical stage.

As giants rule the obesity market, small-cap MetaVia pitches a novel dual-agonist and a first-in-class MASH drug. Can its science win the day?

With 33% growth dwarfing industry norms, NNB Nutrition's integrated model and fermentation tech aren't just winning—they're rewriting the rules for wellness.